All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @thatsarajane on TikTok · 55s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @thatsarajane's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00This is how my first month of Monjaro went.
  2. 0:02Had researched every article, every bad review, every horror story, and it was very unhelpful to me.
  3. 0:08It worked pretty much instantly.
  4. 0:11My food noise was gone, I did not think about it, I did not sit in bed and washer had toast,
  5. 0:16or biscuits, or crisps. I didn't get any side effects other than being thirsty, no bad side
  6. 0:22effects whatsoever. Something that was a struggle was forcing myself to eat, even though I wasn't
  7. 0:27hungry because the novelty of not being hungry for the first time in my life was sort of egging me
  8. 0:33on to just not eat anything at all. The biggest and best thing about starting this is the headspace
  9. 0:40that I have created from not thinking about food. I just, I'm hungry, I eat something, that is good
  10. 0:47for my body and that is that, it's done. I would say just remember starting at anything never scary,
  11. 0:52but being trapped is scarier.

@thatsarajane's Mounjaro update, fact-checked

Sara-Jane

TikTok creator

574.8K viewsWatch on TikTok

Quick answer

Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist approved for glycemic control in type 2 diabetes and, as Zepbound, for chronic weight management in adults with obesity or overweight with a related comorbidity. The appetite suppression and reduced food preoccupation described by the creator are consistent with the drug's documented mechanisms, including delayed gastric emptying and central appetite regulation. Gastrointestinal side effects remain the most common adverse events in clinical trials, occurring in the majority of participants at therapeutic doses, making a fully symptom-free titration period uncommon though not impossible.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @thatsarajane's Mounjaro update, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@thatsarajane's Mounjaro update, fact-checked" from Sara-Jane. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist approved for glycemic control in type 2 diabetes and, as Zepbound, for chronic weight management in adults with obesity or overweight with a related comorbidity.

The reason this review is not generic is the source wording and the canonical claim label "glp1 not a miracle not a horror story just what actually happen." In this clip, the useful excerpt is: "This is how my first month of Monjaro went." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Gastrointestinal side effects affected the majority of tirzepatide participants in clinical trials.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist approved for glycemic control in type 2 diabetes and, as Zepbound, for chronic weight management in adults with obesity or overweight with a related comorbidity.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist approved for glycemic control in type 2 diabetes and, as Zepbound, for chronic weight management in adults with obesity or overweight with a related comorbidity. The appetite suppression and reduced food preoccupation described by the creator are consistent with the drug's documented mechanisms, including delayed gastric emptying and central appetite regulation. Gastrointestinal side effects remain the most common adverse events in clinical trials, occurring in the majority of participants at therapeutic doses, making a fully symptom-free titration period uncommon though not impossible.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide reduced body weight by up to 22.5 percent over 72 weeks in adults with obesity, with appetite suppression as a primary mechanism.
  • Gastrointestinal side effects affected the majority of tirzepatide participants in clinical trials. A completely symptom-free first month is possible but not the statistical norm.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide reduced body weight by up to 22.5 percent over 72 weeks in adults with obesity, with appetite suppression as a primary mechanism.
  • Gastrointestinal side effects affected the majority of tirzepatide participants in clinical trials. A completely symptom-free first month is possible but not the statistical norm.
  • Mϕller et al. (2022, Diabetes, Obesity and Metabolism) documented reduced food preoccupation as a distinct psychological effect of GLP-1 therapy, separate from simple hunger reduction.
  • Under-eating on tirzepatide is a genuine clinical concern. Without adequate protein intake, weight loss can include significant muscle mass loss alongside fat.
  • Tirzepatide requires a prescription and medical supervision. It is not appropriate for everyone, and suitability depends on individual health history, comorbidities, and other medications.
  • Compounded tirzepatide is not equivalent to FDA-approved Mounjaro or Zepbound. Patients should ask prescribers direct questions about sourcing and regulatory status of any formulation offered.
  • One person's first-month experience, positive or negative, is a single data point. Individual responses to tirzepatide vary considerably based on dose, starting health status, and titration schedule.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @thatsarajane actually say?

She described her first month on Mounjaro as largely positive and uneventful. "Food noise was gone," she said, and she experienced no significant side effects beyond thirst. She also admitted to struggling to eat enough because not being hungry felt so novel. Her closing line was that "starting at anything never scary, but being trapped is scarier." No miracle claims. No medical advice. Just a personal account.

That framing matters. She was not telling anyone to take Mounjaro. She was describing what happened to her. The video is anecdote, not instruction. That distinction is important before we get into what the science actually says about her experience.

Does the science back this up?

Mostly, yes, with one significant caveat about side effects. The "food noise" reduction she describes is one of the more consistently reported and studied effects of GLP-1 and GIP/GLP-1 dual agonists. The near-zero appetite response she experienced tracks with the clinical data.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide, the active ingredient in Mounjaro, produced significant appetite suppression and reduced caloric intake in participants with obesity. Qualitative research has backed up the "food noise" language specifically. Mϕller et al. (2022, Diabetes, Obesity and Metabolism) documented that GLP-1 receptor agonists reduce preoccupation with food as a distinct psychological effect, not just reduced hunger. So when she says she stopped lying in bed thinking about toast and biscuits, that is a real, documented pharmacological effect, not placebo.

The thirst she mentions is also plausible. Tirzepatide can affect fluid balance, and increased water intake is a commonly self-reported behavior change, though it is not a formally listed adverse effect in the prescribing information.

What did they get wrong (or right)?

The side effect claim is where this gets complicated. Saying she had "no bad side effects whatsoever" is her honest experience, but it is statistically unusual, and presenting it without context could set unrealistic expectations for viewers.

In SURMOUNT-1, gastrointestinal side effects affected a majority of participants at the 5mg and 10mg dose levels. Nausea was reported in roughly 30 percent of participants at the lower dose and climbed higher with dose escalation. Vomiting, diarrhea, and constipation were also common. Her experience is real. It is just not typical, especially at higher doses or during titration. Calling it "no bad side effects whatsoever" as a general take rather than a personal one is the one place this video could genuinely mislead someone.

What she got right: the framing around mental headspace and the psychological weight of food obsession is clinically underappreciated. Researchers like Tronieri et al. (2023, Obesity Reviews) have argued that the cognitive and psychological burden of chronic food preoccupation is a legitimate treatment outcome that trial endpoints often fail to capture. She named something real.

What should you actually know?

A few things are worth being clear about if you are watching this video and considering Mounjaro or any GLP-1 based medication.

  • Tirzepatide is approved in the US and UK for type 2 diabetes (as Mounjaro) and weight management (as Zepbound in the US). It is a prescription medication. A licensed prescriber needs to evaluate whether it is appropriate for you.
  • Side effects are common. The clinical trial data is unambiguous on this. A side-effect-free first month happens, but it is the exception, not the rule. Prepare for the possibility of nausea, particularly during dose increases.
  • The under-eating she describes is a real risk. Not eating enough while on tirzepatide can result in muscle loss. Adequate protein intake and medical supervision during the medication are not optional extras.
  • Compounded tirzepatide is not the same as FDA-approved Mounjaro or Zepbound. If you are being offered a compounded version, ask direct questions about sourcing and oversight.
  • One month is a short window. Long-term outcomes, including what happens if you stop the medication, are a separate and important conversation to have with your prescriber.

Bottom line

This is a good-faith personal account that gets more right than wrong. The food noise reduction is real. The mental health angle is legitimate and underreported. The side effect experience is genuine but atypical enough that it should carry a bigger asterisk than she gave it. She is not selling anything. She is not prescribing anything. She is just telling her story, which is fine, as long as viewers remember that her story is one data point.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Sara-Jane · TikTok creator

574.8K views on this video

Not a miracle. Not a horror story. Just what actually happened my first month on Mounjaro. #mounjaroupdate #startingmounjaro #glp1community

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) found tirzepatide reduced body?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide reduced body weight by up to 22.5 percent over 72 weeks in adults with obesity, with appetite suppression as a primary mechanism.

What does the video say about gastrointestinal side effects affected the majority of tirzepatide participants in?

Gastrointestinal side effects affected the majority of tirzepatide participants in clinical trials. A completely symptom-free first month is possible but not the statistical norm.

What does the video say about mϕller et al. (2022, diabetes, obesity?

Mϕller et al. (2022, Diabetes, Obesity and Metabolism) documented reduced food preoccupation as a distinct psychological effect of GLP-1 therapy, separate from simple hunger reduction.

What does the video say about under-eating on tirzepatide?

Under-eating on tirzepatide is a genuine clinical concern. Without adequate protein intake, weight loss can include significant muscle mass loss alongside fat.

What does the video say about tirzepatide requires a prescription?

Tirzepatide requires a prescription and medical supervision. It is not appropriate for everyone, and suitability depends on individual health history, comorbidities, and other medications.

What does the video say about compounded tirzepatide?

Compounded tirzepatide is not equivalent to FDA-approved Mounjaro or Zepbound. Patients should ask prescribers direct questions about sourcing and regulatory status of any formulation offered.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Sara-Jane, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.